LifeSci Capital Initiates Coverage of Medicrea

Developing Patient-Specific Spinal Implants to Improve Surgical Outcomes; Report Available here: http://www.lifescicapital.com/equity-research/medicrea/

NEW YORK, NY / ACCESSWIRE / January 26, 2016 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Medicrea (NYSE Euronext: ALMED.PA), a medical device company developing a range of patient-specific implants intended to reshape the spinal fusion market. The Company’s UNiD platform provides spinal surgeons with patient-specific osteosynthesis rods and comprehensive preoperative planning solutions intended to improve postoperative spinal alignment and patient outcomes. Medicrea is also a leader in the emerging field of 3D printing, offering patient-specific interbody cages and vertebral bodies. Medicrea’s focus on the personalization of spine treatment differentiates the Company from others in the space.

Osteosynthesis rods are used in most spinal fusion surgeries to fix and promote fusion of vertebrae into a proper alignment. Medicrea has developed a process for the design and manufacture of patient-specific rods, known as UNiD rods, which may provide a more natural spinal curvature than current methods. At present, the rods are bent manually in the operating room resulting in 62% of patients experiencing postoperative sagittal malalignment and 37% of patients requiring revision surgery over the long term. These revision procedures carry a high additional cost and have higher complication rates than the original surgery. In addition, sagittal alignment is recognized as an important predictor of patient outcomes and quality of life.

Medicrea controls its entire supply chain, enabling high sales margins around 80%. Medicrea presently sells its products within 25 countries through a combination of direct sales and distribution partnerships. The Company has recently expanded its sales force, particularly in the US, in order to increase its footprint in the spinal market.

In a 27 page Initiation Report, LifeSci Capital explains the importance of spinal alignment in predicting patient outcomes and how Medicrea’s UNiD patient-specific technology may improve upon existing methods of spinal fusion. The report also discusses both the market opportunity for Medicrea and savings to the healthcare system from the greater use of patient-specific technology in the spine market.

Dr. Isaacson’s full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on Medicrea as developments occur.

The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company’s website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com

SOURCE: LifeSci Capital, LLC

ReleaseID: 436015